Clinical Trials Logo

Filter by:
NCT ID: NCT05001542 Completed - Distress, Emotional Clinical Trials

Digital Interventions for Detection and Reduction of Moral Distress

VR
Start date: May 31, 2021
Phase: N/A
Study type: Interventional

Stress, anxiety, distress and depression are exceptionally high among healthcare workers at the frontline of the COVID-19 pandemic. Factors underlying distress and resilience are unknown and there are no evidence based interventions to impact the mental wellbeing of frontline healthcare workers. This study will evaluate a novel virtual reality platform to gather the "distress experience" of frontline healthcare workers at Unity Health Toronto in real time during the ongoing COVID pandemic by developing and showing feasibility of digital technology (Virtual Reality (VR) and mobile app) as a digital platform to understand the causes and ultimately reduce the moral distress of healthcare providers during the COVID-19 pandemic. The project will develop innovations which can be used for future pandemics and other contexts prone to producing moral distress and injury.

NCT ID: NCT05001269 Recruiting - Clinical trials for Primary Hyperoxaluria

Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function

PHYOX8
Start date: February 22, 2022
Phase: Phase 2
Study type: Interventional

The aim of this study is to evaluate nedosiran in participants 11 years of age and younger who have Primary Hyperoxaluria with relatively intact renal function.

NCT ID: NCT05001048 Completed - Vasodilation Clinical Trials

Sex Differences in Sympathetic Activity and Vascular Reactivity During Acute and Chronic Hypoxia.

Start date: August 4, 2019
Phase: N/A
Study type: Interventional

This study aims to investigate sex differences in blood pressure control associated with exposure to acute hypoxia (low oxygen), and short term acclimatization to hypoxia at high altitude.

NCT ID: NCT05000983 Recruiting - Burns Clinical Trials

A Between Patient Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries

Start date: October 20, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Burn injuries can result in long term physical and mental sequelae, not only from the scarring but also the painful dressings. The standard of care today remains use of antibiotic topical dressings while awaiting demarcation of the burn depth, with surgical excision and grafting for deep partial thickness and full thickness areas. Demarcation can be appreciated on admission for full thickness burns but is often a prolonged process that can last weeks. The clinical evaluation of the depth of the burn is a complex decision that often is made more challenging by the presence of the proteinaceous pseudoeschar and the coagulated dermis itself. Surgical debridement is relatively 'coarse' and by its very nature requires removal of a thin layer of viable tissue to reach the level that is vascularized enough to support a skin graft. There has been growing interest in the use of adjuncts to reduce the amount tissue debrided and potentially reduce the need for surgery itself. Operatively, there have been some reports that use of hydro-dissection devices (Versajetâ„¢) may allow a more controlled debridement, resulting in less viable tissue being sacrificed. There is also a growing experience with enzymatic debridement, especially with Bromolein, derived from Pineapple (NexoBrid®). Neither of these have been shown to definitively improve care in randomized controlled trials, (RCTs) and there is suggestion that in some settings may actually cause harm.

NCT ID: NCT05000138 Recruiting - Clinical trials for Giant Cell Arteritis

FDG Digital PET/CT as First Line Investigation for Giant Cell Arteritis

Start date: June 10, 2022
Phase:
Study type: Observational

Giant cell arteritis (GCA) causes inflammation of the arteries and can lead to serious complications such as blindness, necessitating rapid diagnosis and treatment. Although older technology non-digital PET/CT scans are routinely used for the diagnosis of GCA in large arteries, they have not been able to reliably detect inflammation of the small arteries responsible for blindness. Recent technological advances have enabled PET/CT imaging of millimetric disease in the body, which are now able to resolve small arteries. In the proposed research study, patients who are suspected by their doctors to have GCA will undergo an ultrasound of the temporal arteries, and digital PET/CT scan after injection of radioactive glucose. Digital PET/CT scans will be interpreted for the presence of abnormal uptake in the large and small arteries, as well as for the presence of other causes of the patient's symptoms. The diagnostic accuracy of PET/CT and ultrasound will be evaluated with respect to an expert panel diagnosis of giant cell arteritis and compared. Results will be adjusted for lack of a perfect reference test using advanced statistics. The goal will be to see if digital PET/CT can become a single, integrated test to diagnose this disease.

NCT ID: NCT04999969 Active, not recruiting - Clinical trials for Locally Advanced or Metastatic Solid Tumours

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

Start date: December 10, 2021
Phase: Phase 2
Study type: Interventional

The proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).

NCT ID: NCT04999839 Completed - Clinical trials for Moderate to Severe Plaque Psoriasis

Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis

Start date: August 11, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2b, randomized, multicenter, double-blind, placebo-controlled, multiple-dose study designed to evaluate the efficacy, safety, and tolerability of NDI-034858 in participants with moderate to severe plaque psoriasis. This study will also evaluate the plasma concentrations of NDI-034858 and explore the immune response to NDI-034858 in participants with moderate to severe plaque psoriasis.

NCT ID: NCT04999553 Recruiting - Depression Clinical Trials

Left vs. Right Non-Inferiority Trial

LeRNIT
Start date: November 8, 2021
Phase: N/A
Study type: Interventional

The aim of this study is to test the hypothesis that low-frequency rTMS (LFR) works as well as the established intermittent thetaburst rTMS (iTBS) treatment for treatment resistant depression (TRD).

NCT ID: NCT04999410 Recruiting - Clinical trials for Apparently Healthy Adults Cycling Performance

Virtual Programming Interval Training for TT Performance

VPHIIT
Start date: November 20, 2020
Phase: N/A
Study type: Interventional

High Intensity Interval Training (HIIT) studies are required to determine the optimal training protocol to improve time trial(TT) performance. Data collection for this study will be conducted virtually through the use of a software platform (www.trainerroad.com) by people in their homes on cycle ergometers. Investigators will recruit people who are familiar with cycle exercise training and have their own equipment. By using a virtual platform to collect data, investigators will extend our reach to include a much larger and diverse sample of adult men and women up to age 45 years. In addition, the software platform will allow participants to train from the safety of their home, preventing the risk of exposure to COVID19. OBJECTIVES O1: The primary objective of this study is to determine the influence of interval work-bout duration on TT performance when total mechanical work is matched. O2: The secondary objective of the study is to determine the influence of work-bout duration on TT performance when work is matched by effort. HYPOTHESIS H1: long duration bouts of HIIT will lead to greater improvements in performance compared to short duration bouts due to larger total amount of work completed during the interval sessions. H2: HIIT will lead to equivalent improvements in performance when work is matched by the participant's rating of effort.

NCT ID: NCT04999215 Recruiting - Clinical trials for Lesion With Known or Suspected F-choline Uptake

Choline-PET: Exploratory Study Assessing the Potential Role of F-choline PET Imaging in New and Emerging Indications

F-choline
Start date: August 1, 2022
Phase: Phase 3
Study type: Interventional

Choline is an important building block of phospholipids in cell membranes. Certain cancers and medical conditions are known to demonstrate increased absorption and incorporation of choline into their cell membranes. 18-F-fluorocholine (F-choline) and 11-C-choline (C-choline) are diagnostic positron emission tomography (PET) radiotracers that can be used to image, in vivo, the metabolism of choline. Both tracers have been extensively studied in prostate cancer and C-choline has obtained US FDA approval for the investigation of recurrent prostate cancer. F-choline is currently not approved for clinical use by the FDA or Health Canada, but it offers many advantages over C-choline due to its better physical characteristics (mainly due to its positron range, shorter and longer half-life). In recent years, reports have started to emerge on broader potential applications of choline PET imaging, particularly for imaging parathyroid adenomas, certain cervical cancers and certain liver cancers. The main objective is to discover and explore potential new and emerging indications in which F-choline could play a role and provide clinically relevant information. Secondary objectives are 1) To assess the safety of F-choline PET imaging using F-choline produced at the CRCHUM; 2) assess changes in patient/disease management following F-choline PET imaging. Researchers hypothesize that F-choline will provide useful and incremental clinical information in a variety of conditions, and outperform the "standard" workup in numerous conditions. F-Choline PET exams will be performed on hybrid PET/CT scanners according to standard procedures. These examinations could be repeated at the discretion of the treating physician (up to a maximum of 4 exams per year) if the treating physician and the research team deem this could provide additional clinically useful information (for example, by helping to assess response to newly started therapy). The results will be provided to the attending physician and any new knowledge could lead to a change in treatment or an investigation of the condition that prompted enrollment in the study.